SyneuRx is developing new drugs on schizophrenia, depression and dementia in order to answer the unmet medical needs in central nervous system (CNS) disorders. Our first few candidate drugs hold great promise to fast track the development process and reach a dominant position in the CNS drug market quickly.
Our competitive advantages include:
Strong drug efficacy: Innovative, breakthrough, new class of drugs. Strong results from world-leading published studies indicate the effectiveness of the drug is better than any existing drugs. When reach the market, the drugs can be as noteworthy as when Prozac was first introduced for depression, if not more.